Drug repurposing or re-profiling has been the hallmark to bring strong business growth and the trend is being followed by majority of the pharmaceutical and biopharmaceutical companies. Among all biologics approved in the U.S. during 2007-2009, 30-40% of them were the drugs repurposed or repositioned. National Institute of Health (NIH), U.S. Department of Health defines drug repurposing as discovering new uses for approved drugs to provide the quickest possible transition from bench to bedside. Drug repurposing opens up various opportunities to answer current unmet medical needs to come up with cost-effective solutions to expensive drug development process. Repurposing or re-profiling of drugs which are suspended due to lack of efficacy or specificity can be a good start over for further development for new indication. Finding new indications for already studied drugs can benefit patients by getting quick access to new treatment choices and also to developer by saving time and money while maintaining its original IP protection. For many expensive indications such as cancer, scrutinizing for anti-cancer activity among dozens of off-patent drugs that have already established their safety is a powerful method opted by majority of the big pharma companies. However, repurposing is not a new strategy and there are bunch of drugs which are repositioned or repurposed, some of them are Raloxifene (approved for treatment of osteoporosis in 2007, originally indicated for breast cancer treatment), Thalidomide (repositioned for use in treatment of leprosy and multiple myeloma in 2006), Rapamycin (repurposed in 1999 for prevention of organ transplant rejection), Sildenafil (originally approved for erectile dysfunction and recently got approved for treatment of angina) and many others.
Requirement of low investment of time and money in the drug development is the prime advantage of drug repurposing and majority of the drugs in pipeline of major pharmaceutical companies are thus adopt this method. Some of the factors accelerating the drug repurposing activities include sunk research cost, ready availably of bioavailability, pharmacology, toxicity profile & pharmacokinetics data, well established manufacturing protocol etc.; which are expected to drive the global drug repurposing market. There are thousands of failed molecules shelved into the drug libraries, which hold vast potential to reposition. Whereas, limited access chemical structure data of drug molecules, lack of funding etc. are some of the factors limiting the growth of global drug repurposing market.
The global Drug Repurposing market was valued at xx million US$ in 2018 and will reach xx million US$ by the end of 2025, growing at a CAGR of xx% during 2019-2025.
This report focuses on Drug Repurposing volume and value at global level, regional level and company level. From a global perspective, this report represents overall Drug Repurposing market size by analyzing historical data and future prospect.
Regionally, this report categorizes the production, apparent consumption, export and import of Drug Repurposing in North America, Europe, China, Japan, Southeast Asia and India.
For each manufacturer covered, this report analyzes their Drug Repurposing manufacturing sites, capacity, production, ex-factory price, revenue and market share in global market.
The following manufacturers are covered:
Astellas Pharma
Biovista
Novartis
AbbVie
Pfizer
Allergan
NuMedii
...
Segment by Regions
North America
Europe
China
Japan
Southeast Asia
India
Segment by Type
Oncology
CNS Diseases
Neurodegenerative Diseases
Others
Segment by Application
Hospitals
Ambulatory Surgical Centers
Others
Summary:
Get latest Market Research Reports on Drug Repurposing. Industry analysis & Market Report on Drug Repurposing is a syndicated market report, published as Global Drug Repurposing Market Professional Survey Report 2019. It is complete Research Study and Industry Analysis of Drug Repurposing market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.